{"product_id":"molecules-engineered-against-oncogenic-proteins-and-cancer-9781394207084","title":"Molecules Engineered Against Oncogenic Proteins","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c\/b\u003e \u003cp\u003e\u003cb\u003eA comprehensive review of the latest molecular advances in cancer treatment\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eFeaturing 91 total small molecule kinase\/KRAS inhibitors, 80 of which are FDA-approved, \u003ci\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c\/i\u003e documents the recent scientific advances that have transformed one of medicine's most challenging areascancer treatment. Most of these inhibitors  specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase\/KRAS inhibitors in clinical trials are presented. \u003c\/p\u003e\u003cp\u003eWith a very well-known chemist as an author, \u003ci\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c\/i\u003e includes information on: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eEach molecule's structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action\u003c\/li\u003e \u003cli\u003eMu\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface vii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1. Introduction 1 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 Types of Protein Kinases 1\u003c\/p\u003e \u003cp\u003e1.2 Protein Kinase Domains 1\u003c\/p\u003e \u003cp\u003e1.3 ATP-Binding Site 2\u003c\/p\u003e \u003cp\u003e1.4 Types of Kinase Inhibitors 3\u003c\/p\u003e \u003cp\u003e1.5 Brief History of Smallmolecule Kinase Inhibitors 5\u003c\/p\u003e \u003cp\u003e1.6 Peak 12-Month Sales for Leading Kinase Inhibitors 7\u003c\/p\u003e \u003cp\u003e1.7 Approved Kinase Inhibitors 7\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2. BCR-ABL Inhibitors 18\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Imatinib* (1) 19\u003c\/p\u003e \u003cp\u003e2.2 Nilotinib* (2) 24\u003c\/p\u003e \u003cp\u003e2.3 Dasatinib* (3) 27\u003c\/p\u003e \u003cp\u003e2.4 Bosutinib* (4) 30\u003c\/p\u003e \u003cp\u003e2.5 Ponatinib* (5) 33\u003c\/p\u003e \u003cp\u003e2.6 Olvermbatinib** (6) 37\u003c\/p\u003e \u003cp\u003e2.7 Asciminib* (7) 38\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3. BTK Inhibitors 43 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Ibrutinib* (8) 45\u003c\/p\u003e \u003cp\u003e3.2 Acalabrutinib* (9) 51\u003c\/p\u003e \u003cp\u003e3.3 Zanubrutinib* (10) 54\u003c\/p\u003e \u003cp\u003e3.4 Tirabrutinib** (11) 57\u003c\/p\u003e \u003cp\u003e3.5 Orelabrutinib** (12) 58\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4. EGFR\/HER Family Inhibitors 59 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Gefitinib* (13) 61\u003c\/p\u003e \u003cp\u003e4.2 Erlotinib * (14) 67\u003c\/p\u003e \u003cp\u003e4.3 Icotinib** (15) 72\u003c\/p\u003e \u003cp\u003e4.4 Afatinib* (16) 74\u003c\/p\u003e \u003cp\u003e4.5 Dacomitinib* (17) 77\u003c\/p\u003e \u003cp\u003e4.6 Osimertinib* (18) 80\u003c\/p\u003e \u003cp\u003e4.7 Mobocertinib* (19) 86\u003c\/p\u003e \u003cp\u003e4.8 Lapatinib* (20) 90\u003c\/p\u003e \u003cp\u003e4.9 Tucatinib* (21) 93\u003c\/p\u003e \u003cp\u003e4.10 Neratinib* (22) 95\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5. VEGFR\/Multikinase Inhibitors 97\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Sorafenib* (23) 99\u003c\/p\u003e \u003cp\u003e5.2 Regorafenib* (24) 104\u003c\/p\u003e \u003cp\u003e5.3 Sunitinib* (25) 106\u003c\/p\u003e \u003cp\u003e5.4 Pazopanib* (26) 112\u003c\/p\u003e \u003cp\u003e5.5 Axitinib* (27) 114\u003c\/p\u003e \u003cp\u003e5.6 Nintedanib* (28) 117\u003c\/p\u003e \u003cp\u003e5.7 Apatinib** (29) 121\u003c\/p\u003e \u003cp\u003e5.8 Lenvatinib* (30) 122\u003c\/p\u003e \u003cp\u003e5.9 Tovozanib* (31) 125\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6. CDK4\/6 Inhibitors 127\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 Palbociclib* (32) 129\u003c\/p\u003e \u003cp\u003e6.2 Ribociclib*(33) 136\u003c\/p\u003e \u003cp\u003e6.3 Abemaciclib* (34) 139\u003c\/p\u003e \u003cp\u003e6.4 Trilaciclib* (35) 142\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7. JAK Inhibitors 144\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Tofacitinib* (36) 147\u003c\/p\u003e \u003cp\u003e7.2 Baricitinib* (37) 151\u003c\/p\u003e \u003cp\u003e7.3 Peficitinib** (38) 153\u003c\/p\u003e \u003cp\u003e7.4 Upadacitinib* (39) 158\u003c\/p\u003e \u003cp\u003e7.5 Delgocitinib** (40) 161\u003c\/p\u003e \u003cp\u003e7.6 Filgotinib** (41) 163\u003c\/p\u003e \u003cp\u003e7.7 Abrocitinib* (42) 166\u003c\/p\u003e \u003cp\u003e7.8 Ruxolitinib* (43) 170\u003c\/p\u003e \u003cp\u003e7.9 Fedratinib* (44) 173\u003c\/p\u003e \u003cp\u003e7.10 Pacritinib* (45) 175\u003c\/p\u003e \u003cp\u003e7.11 Ritlecitinib # (46) 177\u003c\/p\u003e \u003cp\u003e7.12 Brepocitinib # (47) 181\u003c\/p\u003e \u003cp\u003e7.13 Ropsacitinib # (48) 184\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 8. Allosteric TYK2 Inhibitors 187\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Deucravacitinib* (49) 189\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 9. ALK\/multikinase Inhibitors 195\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 Crizotinib* (50) 197\u003c\/p\u003e \u003cp\u003e9.2 Ceritinib* (51) 202\u003c\/p\u003e \u003cp\u003e9.3 Alectinib* (52) 205\u003c\/p\u003e \u003cp\u003e9.4 Brigatinib* (53) 207\u003c\/p\u003e \u003cp\u003e9.5 Lorlatinib* (54) 210\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 10. BRAF\/Multikinase Inhibitors 214\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 Vemurafenib* (55) 216\u003c\/p\u003e \u003cp\u003e10.2 Dabrafenib* (56) 222\u003c\/p\u003e \u003cp\u003e10.3 Encorafenib* (57) 225\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 11. MEK Inhibitors 227\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11.1 Trametinib* (58) 228\u003c\/p\u003e \u003cp\u003e11.2 Cobimetinib* (59) 232\u003c\/p\u003e \u003cp\u003e11.3 Binimetinib* (60) 235\u003c\/p\u003e \u003cp\u003e11.4 Selumetinib* (61) 237\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 12. RET\/Multikinase Inhibitors 240\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12.1 Vandetanib* (62) 242\u003c\/p\u003e \u003cp\u003e12.2 Cabozantinib* (63) 245\u003c\/p\u003e \u003cp\u003e12.3 Selpercatinib* (64) 247\u003c\/p\u003e \u003cp\u003e12.4 Pralsetinib* (65) 251\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 13. FGFR Inhibitors 253\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13.1 Erdafitinib* (66) 255\u003c\/p\u003e \u003cp\u003e13.2 Pemigatinib* (67) 260\u003c\/p\u003e \u003cp\u003e13.3 Infigratinib* (68) 263\u003c\/p\u003e \u003cp\u003e13.4 Futibatinib* (69) 265\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 14. PI3K Inhibitors 267\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14.1 Alpelisib* (70) 269\u003c\/p\u003e \u003cp\u003e14.2 Idelalisib* (71) 273\u003c\/p\u003e \u003cp\u003e14.3 Duvelisib* (72) 277\u003c\/p\u003e \u003cp\u003e14.4 Umbralisib* (73) 279\u003c\/p\u003e \u003cp\u003e14.5 Copanlisib* (74) 281\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 15. TRK\/Multikinase Inhibitors 284\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15.1 Larotrectinib* (75) 285\u003c\/p\u003e \u003cp\u003e15.2 Entrectinib* (76) 288\u003c\/p\u003e \u003cp\u003e15.3 Repotrectinib # (77) 291\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 16. MET Inhibitors 294\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16.1 Capmatinib* (78) 295\u003c\/p\u003e \u003cp\u003e16.2 Tepotinib* (79) 297\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 17. KIT\/PDGFR\/Multkinase Inhibitors 299\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e17.1 Avapritinib* (80) 301\u003c\/p\u003e \u003cp\u003e17.2 Ripretinib* (81) 304\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 18. FLT3 Inhibitors 306\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18.1 Midostaurin* (82) 308\u003c\/p\u003e \u003cp\u003e18.2 Gilteritinib* (83) 313\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 19. mTOR Inhibitors 315\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19.1 Sirolimus* and Analogs (84) 317\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 20. Other Kinase Inhibitors 322\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20.1 Netarsudil* (85) 324\u003c\/p\u003e \u003cp\u003e20.2 Belumosudil* (86) 326\u003c\/p\u003e \u003cp\u003e20.3 Fostamatinib* (87) 328\u003c\/p\u003e \u003cp\u003e20.4 Pexidartinib* (88) 331\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 21. KRAS Inhibitors 335\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e21.1 Sotorasib* (89) 337\u003c\/p\u003e \u003cp\u003e21.2 Adagrasib* (90) 346\u003c\/p\u003e \u003cp\u003e21.3 Jdq443 # (91) 350\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 22. An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases 353\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22.1 High-quality Leads 353\u003c\/p\u003e \u003cp\u003e22.2 Integrating Substructures from Different High Quality Leads or Established Inhibitors 355\u003c\/p\u003e \u003cp\u003e22.3 Variation of Hinge-binding Nucleus 357\u003c\/p\u003e \u003cp\u003e22.4 Macrocyclization 359\u003c\/p\u003e \u003cp\u003e22.5 Fragment-based Approach 360\u003c\/p\u003e \u003cp\u003e22.6 Covalent Inhibitors 361\u003c\/p\u003e \u003cp\u003e22.7 Strategic Structural Modification of Prior Drugs 362\u003c\/p\u003e \u003cp\u003e22.8 Exploiting a Specific Kinase Pocket to Optimize Selectivity 364\u003c\/p\u003e \u003cp\u003e22.9 Solvent-exposed Appendages to Enhance Solubility and PK Properties 367\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 23. Targeted Molecular Anticancer Therapies – Successes and Challenges 368\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e23.1 The Beginning 368\u003c\/p\u003e \u003cp\u003e23.2 Further Developments 368\u003c\/p\u003e \u003cp\u003e23.3 Biomarker-driven Drug Development 369\u003c\/p\u003e \u003cp\u003e23.4 Mitigation of Drug Resistance 370\u003c\/p\u003e \u003cp\u003e23.5 Miscellaneous Approaches 371\u003c\/p\u003e \u003cp\u003e23.6 Discovery Chemistry 373\u003c\/p\u003e \u003cp\u003eAppendix 1. First FDA Approvals by Year 374\u003c\/p\u003e \u003cp\u003eAppendix 2. Kinase\/KRAS Inhibitors in Development 375\u003c\/p\u003e \u003cp\u003eAppendix 3. Visualization of Differentially Expressed Kinases in Cancer 378\u003c\/p\u003e \u003cp\u003eAppendix 4. M \u0026amp; A Transactions Driven by Oncology-focused Kinase and KRAS Inhibitors 379\u003c\/p\u003e \u003cp\u003eAppendix 5. Alphabetic List of Oncogenic Protein Inhibitors 380\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407604556119,"sku":"9781394207084","price":119.7,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781394207084.jpg?v=1730499912","url":"https:\/\/bookcurl.com\/products\/molecules-engineered-against-oncogenic-proteins-and-cancer-9781394207084","provider":"Book Curl","version":"1.0","type":"link"}